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Abstract Heterologous trans-splicing is a messenger RNA
(mRNA) processing mechanism, that joins RNA segments from
separate transcripts to generate functional mRNA molecules. We
present here for the first time experimental evidence that the
proximal segment of the HIV-nef RNA segment can be trans-
spliced to both viral (e.g. SV40 T-antigen) and cellular
transcripts. Following either microinjection of in vitro synthe-
sized HIV-nef and SV40 T-antigen pre-mRNA or transfection of
the HIV-nef DNA into T-antigen positive cells (CV1-B3; Cos7),
it was found that recipient cells synthesized HIV-nef/T-antigen
hybrid mRNA and protein molecules. To generate the hybrid
mRNA, the cells utilized the 5P cryptic splice sites of the HIV-nef
(5Pcry 66 and 5Pcry 74) and the SV40 T/t-antigen 3P splice site.
To demonstrate that heterologous trans-splicing also occurs
between the HIV-nef RNA and cellular transcripts, a cDNA
library was established from HIV-nef positive CV1-B3 cells
(CV1-B3/13 cells) and screened for hybrid mRNA molecules.
Reverse transcription-PCR and Northern blot analysis revealed
that a significant portion of the HIV-nef transcript is involved in
heterologous trans-splicing. To date, eight independent HIV-nef/
cellular hybrid mRNA molecules have been identified. Five of
these isolates contain segments from known cellular genes
(KIAA1454, PTPU, Alu and transposon gene families), while
three hybrid segments contain sequences of not yet known
cellular genes (genes 1^3). ß 2001 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
In mammalian cells, numerous messenger RNAs (mRNAs)
are generated by alternative cis-splicing, an RNA processing
mechanism which increases the coding capacity of genes [1].
To achieve this diversity, cells utilize di¡erent splice donor or
acceptor sites within a single pre-mRNA molecule to generate
distinct mRNA molecules. The mRNA variations generated
by alternative cis-splicing include exon inclusion and exon
skipping leading to addition or deletion of functional protein
domains. The change of the reading frame through alternative
cis-splicing causes synthesis of truncated proteins or protein
variants with divergent amino acid compositions. Splice site
selection requires numerous cis- and trans-acting elements
such as splicing enhancers and SR proteins [2,3]. Using the
host cell spliceosome machinery, DNA and RNA viruses such
as SV40 and HIV also frequently increase their coding ca-
pacity to synthesize regulatory and structural proteins by
means of alternative splicing [4,5].
The mRNA and protein diversity can further be increased
through trans-splicing. This RNA maturation mechanism con-
nects RNA segments from two distinct transcripts to generate
a single mRNA molecule [6,7]. To generate the mRNA by
‘homologous’ trans-splicing, cells utilize transcripts from one
gene and synthesize protein isoforms that frequently contain
domain duplications [8^13]. In contrast, ‘heterologous’ trans-
splicing combines RNA segments from unrelated transcripts
and the cells generate hybrid proteins which can contain func-
tional domains encoded by di¡erent genes [14]. In both cases,
one pre-mRNA molecule provides the donor 5P splice site
while the second provides the 3P splice site with the corre-
sponding branch point. As in cis-splicing, trans-splicing pro-
ceeds through two trans-esteri¢cation steps resulting in the
linking of two RNA fragments by a phosphodiester bond.
The features of a transcript that lead to trans-splicing are
not yet known. However, this RNA processing event can be
expected when cellular or viral pre-mRNA molecules contain
cryptic splice sites that are not accessible for regular cis-splic-
ing [8]. In this regard it is noteworthy that the HIV-nef gene
contains two 5P cryptic splice sites (consensus splice site se-
quences reviewed in [15]). The nucleotide sequences of these
cryptic splice sites correspond to the HIV-nef codons 66^67
(5Pcry 66) and 74^75 (5Pcry 74; Fig. 1A). Since HIV-nef RNA
itself has no introns and is localized at the 3P end of the viral
genome, these 5P cryptic donor splice sites are not accessible
for conventional cis-splicing. This suggests the possibility that
HIV-nef RNA may undergo heterologous trans-splicing with
either viral or cellular pre-mRNA molecules.
The aim of the present study is to explore whether the HIV-
nef RNA 5P cryptic splice sites are indeed used by mammalian
cells to generate hybrid mRNA molecules and proteins by
heterologous trans-splicing. In the ¢rst set of experiments,
we analyzed formation of HIV-nef/T-antigen mRNAs in
CV1 monkey cells. To exclude alternative mechanisms such
as DNA recombination or alternative cis-splicing, we com-
bined in vitro pre-mRNA synthesis (cRNA) and in vivo
mRNA processing in microinjected CV1 cells [16]. After intra-
nuclear injection of HIV-nef and SV40 T-antigen cRNAs, the
presence of hybrid HIV-nef/T-antigen mRNA and protein
molecules was demonstrable by reverse transcription (RT)-
PCR analysis, immuno£uorescence staining and Western
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blot analysis. To explore whether HIV-nef RNA also forms
hybrid mRNA molecules with cellular transcripts, the pCMV-
HIV-nef DNA was microinjected into the nuclei of T-antigen
positive CV1 cells (CV1-B3), and HIV-nef positive cell lines
were established (e.g. CV1-B3/13). A CV1-B3/13 cDNA li-
brary was generated and screened for trans-spliced mRNAs.
To date, eight independent HIV trans-splice products that
contain the HIV-nef sequence in the proximal part and the
cellular sequences in the distal part have been identi¢ed. In
each case, the joining points between the viral and cellular
segments of the hybrid mRNAs were the HIV-nef cryptic
5P splice sites 66 or 74 and the 3P splice acceptor sites of
cellular transcripts.
2. Materials and methods
2.1. Cell culture and generation of cell lines
CV1 cells were cultured in Dulbecco’s modi¢ed Eagle medium (Gib-
co BRL Life Technologies) supplemented with 10% fetal calf serum.
The CV1-B3 cell line was obtained after microinjection of the pSV
Taq/Bam v-5Pt v-5Pcry construct into CV1 cells, followed by Zeocin1
(Invitrogen) selection. For generation of the CV1-B3/13 cell line, the
pCMV-£ag/HIV-nef DNA (encoding the Nef protein with an N-ter-
minal £ag epitope) was microinjected into the CV1-B3 cells (one to
two DNA molecules per cell ; [17]) and cell clones positive for the
HIV-nef gene were selected (G418 and Zeocin1). CV1-B3 cells were
transfected by the calcium phosphate method with the pCMV-£ag/
HIV-nef/PTPU DNA and stable cell lines were obtained by G418
selection. Jurkat cells were cultured in RPMI (Gibco BRL Life Tech-
nologies) supplemented with 10% fetal calf serum. pCMV-£ag/HIV-
nef DNA was transfected by the DEAE-dextran method. Shortly,
1^2U107 Jurkat cells were resuspended in 2 ml phosphate-bu¡ered
saline (PBS); 5 Wg DNA in 1 ml PBS and 5 mg DEAE-dextran in 2 ml
PBS were added to the cells, which were then incubated for 1 h at
37‡C. The cells were washed twice with medium and further cultured
for 48 h.
2.2. Plasmid constructs
The T7-Taq/Bam construct (T7-Taq/Bam v-5Pt v-5Pcry) contains
the early SV40 Taq/BamHI DNA fragment with the small t-antigen
5P splice site and the large T-antigen cryptic 5P splice site at codons
132/133, inactivated by site-directed mutagenesis [8] and inserted into
pSPT 19 (Pharmacia). The pSV Taq/Bam v-5Pt v-5Pcry contains the
same DNA fragment inserted in the multiple cloning site of pTracer-
SV40 (Invitrogen). The pT7-HIV-nef contains the HIV-1 nef BamHI/
NotI DNA fragment (HIV-Eli strain nucleotide sequence 8012^9754;
[18]) inserted into the multiple cloning site of pcDNA3 (Invitrogen).
From this construct, the T7-HIV-nef v-5P/74 DNA was obtained by
converting the consensus 5P splice sequence CAG/GTA to CAG/CTG
by site-directed mutagenesis. To obtain the pCMV-£ag/HIV-nef con-
struct, the ¢rst ATG of the HIV-nef gene was deleted and the £ag-
nucleotide sequence with an additional ATG was added in reading
frame to the 5P end of the HIV-nef coding region. The pCMV-£ag-
nef/PTPU construct contains nef/PTPU hybrid DNA obtained from
the CV1-B3/13 cDNA library by PCR ampli¢cation (primer pair
n6^P1), with the £ag-nucleotide sequence inserted into the multiple
cloning site of pcDNA3. The accuracy of all constructs was con¢rmed
by DNA sequencing with the Applied Biosystems Model 373 A utiliz-
ing dye terminators (Perkin Elmer).
2.3. In vitro RNA synthesis and microinjection
T7-HIV-nef and T7-Taq/Bam plasmids were treated with NotI and
SmaI endonucleases, respectively. 1 Wg of the linearized DNA tem-
plates was transcribed in vitro with T7 RNA polymerase (T7 Cap-
Scribe; Roche) according to the supplier’s protocol. Non-capped
cRNA molecules were obtained by omission of the cap nucleotide
m7G(5P)ppp(5P)G (Ambion) in the transcription reaction. DNA tem-
plates were removed by RQ-I-DNase (Promega) treatment. The
DNA-free status of the cRNA preparations was con¢rmed by PCR
analysis. The PCR products were separated on 2% agarose gels, visu-
alized by ethidium bromide staining and subjected to Southern blot
analysis as described elsewhere [19]. CV1 cells were microinjected with
either capped or non-capped cRNA molecules (concentration 1 Wg/Wl,
injection volume 1038 Wl/cell). Two hours after injection RNA was
extracted from the recipient cells using the Trizol reagent kit, follow-
ing the protocol of the supplier (Gibco BRL Life Technologies).
2.4. RNA isolation
Total RNA was extracted with guanidine isothiocyanate and puri-
¢ed by centrifugation through a CsCl cushion [19]. The mRNAs were
isolated with the PolyATract mRNA isolation system according to the
supplier’s instructions (Promega). 1 Wg of mRNA and 5 ng of in vitro
synthesized cRNA were subjected to agarose gel electrophoresis under
denaturing conditions (formamide/formaldehyde bu¡er) and were
then processed for Northern blotting as described elsewhere [19].
The blots were hybridized with probes labelled with the DIG lumi-
nescence detection kit (Roche Diagnostics).
2.5. RT-PCR ampli¢cation
1 Wg of total RNA was reverse-transcribed into cDNA with 200
units of super Script RT (Gibco BRL Life Technologies). For syn-
thesis of the ¢rst DNA strand, 0.5 Wg of a modi¢ed oligo (dT)15
primer mdT was used in a ¢nal volume of 20 Wl enzyme bu¡er (Gibco
BRL Life Technologies) according to the supplier’s instructions. Syn-
thesis of the second-strand synthesis was performed with Taq poly-
merase (Gibco BRL Life Technologies) utilizing either the HIV-nef
primer n or the T-antigen primer T. 100 ng of cDNA was then am-
pli¢ed in a 50 Wl reaction volume containing 20 mM Tris pH 8.0, 50
mM KCl, 2 mM MgCl2, 200 WM of each deoxynucleotide triphos-
phate, 25 pmol of each primer and 1.25 units of Taq DNA polymer-
ase (Gibco BRL Life Technologies). The cycling pro¢le was 94‡C for
45 s, 50/55/60‡C for 45 s, 72‡C for 1 min and a ¢nal extension at 72‡C
for 10 min.
The primer sets used in this investigation were as follows: n : 5P-
AAG GGT GGC AAA TGG TCA-3P ; n1 : 5P-GTA GGA GCA GTA
TCT CGA GAC-3P ; n2 : 5P-CCC TTG TAG CAA GCT CGA TGT
C-3P ; n3 : 5P-CCT GGA AAA ACA TGG GGC AAT CAC-3P ; n4 :
5P-GGG ATG GCC TGC TAT AAG GG-3P ; n5 : 5P-CCA GCA
GCA GAT GGG GTA GG-3P and n6 : 5P-GAC CTG GAA AAA
CAT GGG GC-3P for nef; T : 5P-ATT CCA ACC TAT GGA ACT-
3P ; T1 : 5P-GAA ATG CCA TCT AGT GAT-3P ; T2 : 5P-GTT ATG
ATT ATA ACT GTT ATG-3P and T3 : 5P-ACT AAA CAC AGC
ATG ACT C-3P ; T4 : 5P-AGG AAA GTC CTT GGG GTC TT-3P
for T-antigen. K : 5P-GCC GCT CTT CTC CAT CTT TC-3P for
KIAA1445. P : 5P-CAG CTT TTC TTC AAA GCA GGG-3P and
P1 : 5P-GAC AGA TGC TAC TGA GTA TTT A-3P for PTPU. g1 :
5P-CTG CAA CCT AAC CAG GCT TCT TG-3P for gene 1. g2 : 5P-
GGA GGA GCC ATG TGG CAA GG-3Pfor gene 2. g3 : 5P-GCA
GCC CCT TGC ATG TCA C-3P for gene 3. t : 5P-GGC GGT TGC
TGA AGA TTG GAG-3P for transposon. a : 5P-TAC CAT ACT
GGC CAG GCT GG-3P for Alu. G : 5P-CCC CTT CAT TGA CCT
CAA CTA C-3P ; G1 : 5P-TTG AAG TCG CAG GAG ACA ACC-3P
for GADPH and mdT : 5P-GAT GGC GAA CTT GTC ACA
Gp(dT)25-3P and mdT1 : 5P-GAT GGC GAA CTT GTC ACA GT-
3P for the cDNA library. The PCR products were sequenced as men-
tioned above.
2.6. Construction of the CV1-B3/13 cDNA library
The cDNA obtained from CV1-B3/13 cells was ampli¢ed using the
primer pair n4^mdT1. The PCR fragments obtained were sub-cloned
in the pCRII-TOPO cloning vector and propagated in Escherichia coli
strain TOP10PF, according to the manufacturer’s recommendations
(Invitrogen). Bacterial colonies were transferred to positively charged
nylon membranes (Boehringer Mannheim) and treated with protein-
ase K according to the supplier’s instructions. The blots were hybrid-
ized with two di¡erent HIV-nef DNA DIG-labelled probes, the ¢rst
containing the nucleotide sequence corresponding to the HIV-nef ami-
no acids 1^66, while the second probe contained the nucleotide se-
quence corresponding to amino acids 75^206. The appropriate clones
were selected and grown up overnight in 5 ml LB medium. The plas-
mids were isolated with the Rapid Plasmid Miniprep System (Gibco
BRL Life Technologies) and sequenced as described above.
2.7. Immuno£uorescence staining of microinjected cells
Eight hours after microinjection CV1 cells were air-dried, ¢xed with
ice cold methanol for 10 min and stained with either polyclonal HIV-1
BH10 Nef antibody (NIH AIDS Research and Reference Reagent
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Program, diluted 1:100) or monoclonal SV40 T-antigen antibody Ab-
2 (Oncogene, diluted 1:10) for 45 min at 37‡C. The secondary anti-
body for Nef staining was £uorescein-conjugated, while the secondary
antibody for T-antigen was rhodamine-conjugated (Jackson Immuno-
research Laboratories, Inc., Baltimore, MD, USA).
2.8. Western blot analysis
Cell lysates were prepared from CV1-B3, CV1-B3/13 and CV1-768
cells (lysis bu¡er: 50 mM Tris^HCl, pH 7.8, 150 mM NaCl, 2.5 mM
EDTA, 1% NP-40, 1 mM PMSF and 1 Wg/ml of each of the protease
inhibitors pepstatin, aprotinin and leupeptin). Protein extracts (500
Wg) were treated with the HIV-1 Nef BH10 antiserum (NIH AIDS
Research and Reference Reagent Program) and Protein A (Pierce).
The immunoprecipitates were separated on a 7.5% SDS^polyacryl-
amide gel, electroblotted onto PVDF membrane (Roth) and probed
with SV40 T-antigen antibody Ab-2 (Oncogene). After stripping the
immunoprecipitates were then re-hybridized with monoclonal £ag
antibody (Sigma). The blot was developed with the chemilumines-
cence detection system (NEN).
2.9. Two-dimensional (2D) electrophoresis
2D electrophoresis was performed as described elsewhere [20]. in
short, 1U108 cells (CV1-B3 and CV1-B3/13) were treated with 0.4 ml
1.5U isoelectric focusing (IEF) bu¡er (10.5 M urea, 3 M thiourea, 6%
CHAPS, 3% immobiline bu¡er pH 3^10, 0.4% dithiothreitol (DTT),
1 mm PMSF, 15 Wg/ml aprotinin, 15 Wg/ml leupeptin, 15 Wg/ml pepsta-
tin, 0.005% bromophenol blue). after 30 min on ice, cell homogenates
were centrifuged at 14 900Ug for 30 min. cell extracts were diluted
with 1U IEF bu¡er to a protein concentration of approximately 14
mg/ml in order to achieve a complete rehydration of the IEF gel
strips, as well as a homogeneous distribution of proteins on the gel.
Each 18 cm IEF gel strip with a non-linear pH gradient of 3^10
(Pharmacia, Uppsala, Sweden) was loaded with 5 mg protein and
allowed to rehydrate overnight at 20‡C. IEF was carried out on a
Pharmacia Multiphor cell, starting at 150 V for 30 min, followed by
300 V for 2 h; the gels were then run at constant voltage of 3500 V for
13 h. SDS^PAGE on the second dimension was performed as de-
scribed elsewhere [20]. After IEF, the gel strips were incubated in
equilibration bu¡er (50 mM Tris^HCl pH 8.8, 6 M urea, 30% glyc-
erol, 2% SDS, 100 mM DTT, 0.005% bromophenol blue) for 15 min
at room temperature. Each gel strip was then placed onto the 10%
SDS^polyacrylamide gel, which was run at 8 mA overnight, in an
electrophoresis chamber from Bio-Rad. Proteins were blotted onto
PVDF membranes at 400 mA for 45 min using a semi-dry cell. Mem-
branes were incubated with HIV-1 Nef BH10 antiserum (NIH Aids
Research and Reference Reagent Program). After incubation with the
peroxidase-conjugated secondary antibody, blots were developed by
enhanced chemiluminescence (NEN Life Science Products). 2D immu-
noblot analysis was performed as described elsewhere [20].
3. Results
3.1. Microinjection of HIV-nef and SV40 T-antigen cRNAs in
CV1 cells generated hybrid mRNA by heterologous
trans-splicing
Fig. 1 indicates the position of the two cryptic 5P splice sites
(5Pcry 66-AG/GTG; 5Pcry 74-AG/GTA; the same sequence as
the SV40 T-antigen 5P splice site) on the HIV-nef gene which
are conserved in the majority of the HIV-1 isolates listed in
the DNA database (National Center for Biotechnology Infor-
mation). The aim of the ¢rst set of experiments was to prove
whether mammalian cells have the capability to trans-splice
the proximal segment of the HIV-nef RNA to other viral
transcripts, using the SV40 T-antigen RNA as a model accep-
tor molecule. To obtain the donor pre-mRNA, the HIV-nef
gene with the 3P LTR sequence was cloned and transcribed in
vitro with T7 RNA polymerase, generating the capped HIV-
nef cRNA (Fig. 1A). To get potential trans-splicing acceptor
pre-mRNA molecules, we transcribed the T7-Taq/Bam DNA,
which encodes the second SV40 T-antigen exon in vitro
(T-antigen cRNA, Fig. 1B). This cRNA contains the T/t-anti-
gen 3P splice site (Fig. 1B), but not the functional 5P splice
sites [8]. In both cases the DNA templates were removed by
extensive DNase treatment; DNA-free conditions were con-
¢rmed by PCR analysis (data not shown). The HIV-nef and
SV40 T-antigen cRNAs were then mixed and microinjected
into the nuclei of CV1 cells (200 cells per test). Two hours
after injection, the cells were lysed and the RNA was ex-
tracted and converted into cDNA applying the oligo (dT)15
primer for synthesis of the ¢rst DNA strand. Utilizing the
HIV-nef T-antigen primer pair n3^T3 for ampli¢cation, the
PCR generated a 327 bp DNA fragment, as predicted when
proximal HIV-nef cRNA segment (HIV-nef codons 1^74) is
trans-spliced to the 3P splice site of T-antigen cRNA (Figs. 1C
and 2A, lane 3). Southern blot analysis con¢rmed that the
327 bp fragment contained HIV-nef as well as SV40 T-antigen
sequences, hybridizing with both the HIV-nef (Fig. 2B, lane 3)
and the SV40 T-antigen probe (Fig. 2C, lane 3). To further
characterize the 327 bp RT-PCR segment, the PCR product
was directly subjected to DNA sequencing. It was demon-
strated that the proximal segment of the 327 bp DNA frag-
ment was HIV-nef-speci¢c and that the distal segment origi-
nated from the T-antigen cRNA. As illustrated in Fig. 1D, the
junction between the two cRNA molecules is the cryptic
5P splice site of the HIV-nef gene (HIV-nef codon 74) and the
3P splice site of the T-antigen (T-antigen codon 83). This veri¢es
that the microinjected cells generated the HIV-nef/T-antigen
hybrid mRNA by heterologous trans-splicing. HIV-nef/T-anti-
gen trans-splicing was also observed when SV40 wtT-antigen
cRNA molecules (containing the authentic T/t-antigen 5P and
3P splice sites) were coinjected with HIV-nef cRNA, although
at a signi¢cant lower e⁄ciency (data not shown).
Moreover, microinjection experiments revealed that e⁄cient
heterologous trans-splicing requires that the cRNA molecules
are capped (Fig. 2F, lane 3), although in vitro polyadenyla-
tion was not essential. After intranuclear injection, HIV-nef/
T-antigen trans-spliced RNA molecules were generated before
polyadenylation occurred in the recipient cells (data not
shown), as recently shown for homologous T-antigen trans-
splicing [16]. To determine whether the HIV-nef 5Pcry splice
site 66 can also be used for trans-splicing, the consensus se-
quence of the 5P splice site 74 was inactivated by site-directed
mutagenesis (Fig. 1A; CAG/GTA to CAG/CTG) and the
corresponding v-5P/74 cRNA was microinjected together
with the T-antigen cRNA. Two hours later the RNA was
re-extracted and converted into cDNA. With the HIV-nef-
and T-antigen-speci¢c primer pair n3^T3 the PCR generated
a 303 bp DNA fragment (Fig. 2D, lane 3). DNA sequencing
of the 303 bp segment revealed that the CV1 cells utilized the
HIV-nef 5Pcry splice site 66 to generate HIV-nef/T-antigen
hybrid mRNA (Fig. 1E). When both HIV-nef 5P cryptic splice
sites were mutated, heterologous trans-splicing was not detect-
able (data not shown).
We further analyzed HIV-nef/T-antigen trans-splicing in
CV1-B3 cells transfected with pCMV-£ag/HIV-nef DNA. Ap-
proximately 48 h after transfection, mRNA was isolated and
converted into cDNA using the oligo (dT)15 primer for the
¢rst-strand and HIV nef primer n for second-strand DNA
synthesis. The cDNA was then PCR-ampli¢ed using the
HIV-nef T-antigen primer pair n3^T3. As shown in Fig. 2G,
lane 3, the PCR generated the 327 bp DNA. Heterologous
trans-splicing between endogenous T-antigen RNA and HIV-
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nef RNA was also demonstrable in Cos7 cells transfected with
the pCMV-£ag/HIV-nef DNA. However, the trans-splice e⁄-
ciency was signi¢cantly lower than in CV1-B3 cells. Synthesis
of the hybrid mRNA was only demonstrable by semi-nested
PCR, utilizing the primer pair n3^T3 for the ¢rst and the
primer pair n3^T4 for the second DNA ampli¢cation, which
generated the expected 286 bp HIV-nef/T-antigen DNA seg-
ment (Fig. 2H, lane 3). This con¢rms our earlier observation
that inactivation or deletion of the conventional T-antigen
5P splice site increases the trans-splice e⁄ciency [8]. DNA se-
quencing experiments proved that the CV1-B3 as well as the
Cos7 cells utilized the HIV-nef 5Pcry splice 74 as the donor
site and the SV40 T/t-antigen 3P splice site as the acceptor site
to generate the hybrid mRNA (data not shown).
Fig. 1. Heterologous trans-splicing model. A: Schematic view of the HIV-nef gene (amino acids 1^206), the T7-HIV-nef DNA with the 5Pcry
splice sites 66 and 74 and the in vitro synthesized HIV-nef cRNAs. Mutated nucleotides of the 5P cryptic splice site 74 are underlined. B: Sche-
matic view of the SV40 T-antigen (amino acids 1^708) and the T7-Taq/Bam DNA used for in vitro Taq/Bam cRNA synthesis. The SV40 T/t-
antigen 3P splice site 83 is indicated. The amino acid 109 is the ¢rst methionine of the second T-antigen exon. The four exonic splicing en-
hancer sequences are marked with asterisks and their relative positions to the 3P splice site are: nucleotides 52^59 (GAGGAAAA); nucleotides
72^79 (AGAAGAAA); nucleotides 132^155 (AAAAAAGAAGAGAAAGGTAGAAGA) and nucleotides 246^256 (AAAGGAAAAAG). C:
The HIV-nef/T-antigen trans-splicing model. The HIV-nef cRNA provides the 5P splice site and the Taq/Bam cRNA the 3P splice site for the
heterologous trans-splicing. D: Part of the 327 bp nucleotide sequence. The proximal segment is the HIV-nef sequence (amino acids 1^74) and
the distal segment the T-antigen sequence (amino acids 83^708). E: Part of the 303 bp nucleotide sequence. The proximal segment is the HIV-
nef sequence (amino acids 1^66) and the distal segment the T-antigen sequence (amino acids 83^708).
FEBS 25352 26-10-01 Cyaan Magenta Geel Zwart
C. Caudevilla et al./FEBS Letters 507 (2001) 269^279272
3.2. The HIV-nef/T-antigen mRNA is translated into hybrid
proteins
The HIV-nef/T-antigen mRNA contains a large open read-
ing frame with the HIV-nef codons 1^74 as the ¢rst exon and
the T-antigen codons 83^708 as the second exon (Fig. 1D). To
test whether the mRNA is translated into the hybrid protein
as expected (Fig. 1D,E), the cRNA-microinjected CV1 cells
were ¢xed and immunostained with the HIV-1 Nef BH10
antiserum (NIH, AIDS Research and Reference Program)
and the T-antigen antibody (Ab-2, Oncogene). The HIV-1
Nef BH10 antiserum recognizes the N-terminal part of the
HIV-Nef protein (epitope within amino acids 1^74, personal
Fig. 2. RT-PCR analysis. RNA was extracted from CV1 cells 2 h after microinjection of the HIV-nef and T-antigen cRNAs (A^C), converted
into cDNA utilizing mdT primer for the ¢rst DNA strand synthesis. For second-strand synthesis either the HIV-nef primer n or the T-antigen
primer T was used. A: PCR products were separated on a 2% agarose gel and visualized by ethidium bromide staining. Lane 1: PCR product
obtained with the T-antigen primer pair T1^T2. Lane 2: PCR product obtained with the HIV-nef primer pair n1^n2. Lane 3: The hybrid HIV-
nef/T-antigen product obtained by nested PCR. The ¢rst ampli¢cation was performed with the primer pair n1^T2 and the second with the
primers n3^T3. B: Southern blot analysis of the PCR products. The blot was hybridized with a DIG-labelled HIV-nef anti-sense RNA probe.
C: The same blot after stripping and re-hybridization with a DIG-labelled T-antigen anti-sense RNA probe. D: Scheme of the primers used to
detect nef/T-antigen trans-splicing by PCR. E: RT-PCR DNA fragments obtained after microinjection of HIV-nef v-5P/74 and T-antigen
cRNAs, separated on a 2% agarose gel and visualized by ethidium bromide staining. F: RT-PCR DNA fragments obtained after microinjection
of the uncapped HIV-nef and T-antigen pre-mRNAs. G: Total RNA was extracted from CV1-B3 cells transfected with the pCMV-£ag/HIV-
nef DNA and converted into cDNA utilizing the above described primer pairs. H: Total RNA was extracted from Cos7 cells transfected with
pCMV-£ag/HIV-nef DNA and converted into cDNA. For semi-nested PCR (lane 3), the ¢rst ampli¢cation reaction was performed with the
primer pair n3^T2 and the second with the HIV-nef/T-antigen primer pair n3^T4.
FEBS 25352 26-10-01 Cyaan Magenta Geel Zwart
C. Caudevilla et al./FEBS Letters 507 (2001) 269^279 273
observation), while the T-antigen antibody (Ab-2) recognizes
the T-antigen amino acid sequence 91^95 [21]. Since the
T-antigen codon 109 is the ¢rst AUG of the second T-antigen
exon (Fig. 1B), the translation product of the unspliced cRNA
contains only the T-antigen amino acid sequence 109^708 (T2-
antigen), which is therefore not recognized by the Ab-2
T-antigen antibody [8]. In contrast, the HIV-Nef/T-antigen
hybrid protein molecules contain the HIV-Nef amino acids
1^74 (or amino acids 1^66) and the T-antigen amino acids
83^708. Therefore, these hybrid proteins are detectable by
both the HIV-1 Nef BH10 and the Ab-2 T-antigen antibodies.
Double staining experiments revealed that up to 50^60% of
the HIV-nef cRNA and T-antigen cRNA-microinjected CV1
cells exhibited both nuclear HIV-1 Nef BH10 as well as
T-antigen (Ab-2)-speci¢c £uorescence staining (Fig. 3A,B).
However, the results of nuclear staining ranged from weak
to strong, indicating that the recipient cells performed trans-
splicing with di¡erent e⁄ciencies. CV1 cells microinjected
with only HIV-nef cRNA predominantly displayed a cytoplas-
mic HIV-1 Nef BH10 £uorescence staining, but stained neg-
ative for T-antigen (Fig. 3C,D). CV1 cells microinjected with
only the T-antigen cRNA were also negative when stained
with Ab-2 antibody (Fig. 3E) but exhibited a strong nuclear
staining when the T-antigen antiserum F, which recognizes the
middle part of the T-antigen, was applied (Fig. 3F).
To identify the HIV-Nef/T-antigen by Western blot analy-
sis, several HIV-nef positive cell lines (e.g. CV1-B3/13) were
established following microinjection of the CMV-HIV-£ag-nef
DNA into the nuclei of CV1-B3 cells. After cell lysis protein
extracts were immunoprecipitated with the HIV-1 Nef BH10
antibody, and the proteins were analyzed by Western blot.
The membrane was ¢rst incubated with the SV40 T-antigen
antibody Ab-2 (Fig. 4A), then re-hybridized with the £ag anti-
body (Fig. 4B) after stripping. As a positive control cell ex-
tracts from the CV1-768 cells were used. These cells contain
the HIV-£ag-nef/Taq-Bam hybrid trans-gene and generate the
HIV-Nef/T-antigen mRNA by cis-splicing (data not shown)
as well as the corresponding Nef/T antigen hybrid protein
(Fig. 4A,B, lane 3). As shown in Fig. 4A,B (lane 2), the
CV1-B3/13 cells synthesize the Nef/T-antigen hybrid protein,
Fig. 3. Immuno£uorescence staining of microinjected cells. CV1 cells were ¢xed and stained with HIV-nef BH10 antibody 8 h after microinjec-
tion of the HIV-nef and T-antigen cRNAs. B: The same cell stained with the monoclonal Ab-2 T-antigen antibody. C: CV1 cells were ¢xed
and stained with the HIV-nef BH10 antibody 8 h after HIV-nef pre-mRNA injection. D: The same injected cells again stained with the Ab-2
T-antigen antibody. E: CV1 cells microinjected only with T-antigen cRNA and stained with Ab-2. F: The same cell stained with the T-antigen
antiserum F (hamster polyclonal, Berlin, Germany), which recognizes the central part of the T-antigen.
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which is not present in the recipient CV1-B3 cells (lane 1). The
Nef/T hybrid protein has the same apparent molecular weight
(Mr) as the hybrid protein synthesized in the CV1-768 cells
(lane 3).
3.3. The CV1-B3/13 cells e⁄ciently trans-splice the proximal
HIV-nef RNA segment to di¡erent cellular transcripts
The above results imply that heterologous trans-splicing
may also occur between HIV-nef RNA and cellular tran-
scripts. To prove this, mRNA was isolated from CV1-B3
and CV1-B3/13 cells and subjected to Northern blot analysis.
As shown in Fig. 5A*, lane 1, the CV1-B3/13 cells synthesized
not only the authentic HIV-nef mRNA of about 1.0 kb (Fig.
5, lane 1), but in addition multiple larger HIV-nef mRNA
isoforms ranging in size from 1.0 to 7.0 kb. None of these
HIV-nef-speci¢c mRNA molecules was synthesized by CV1-
B3 cells (Fig. 5, lane 2).
To identify possible hybrid mRNA molecules that contain
HIV-nef as well as cellular sequences, the CV1-B3/13 mRNA
was converted into cDNA using a modi¢ed oligo (dT)15 prim-
er (mdT) for ¢rst-strand and the HIV-nef-speci¢c primer n for
second-strand DNA synthesis. The cDNA was then inserted
into the multiple cloning site of the pCRII-TOPO cloning
vector and propagated in E. coli. Replica ¢lters with the bac-
terial colonies were prepared and hybridized with a cDNA
probe speci¢c for either the amino-terminal part of HIV-nef
(amino acids 1^74) or the carboxy-terminal segment (amino
acids 75^206). In this way, approximately 300 clones were
identi¢ed that hybridized with the amino-terminal but not
with the carboxy-terminal probe. These colonies were further
propagated and the inserts were characterized by DNA se-
quencing. As shown in Fig. 6B, eight di¡erent trans-splice
products have been identi¢ed so far that contain HIV-nef
sequences in the proximal part and cellular sequences in the
distal part. Five out of the eight isolates contained segments
of known cellular genes (KIAA1454, PTPU, Alu and trans-
poson gene families) and the other three hybrid molecules
contained sequences of not yet identi¢ed cellular genes (genes
1^3). As expected, several isolates contained the HIV-nef/T-
antigen hybrid DNA. In all analyzed cases, the junction be-
tween the HIV-nef and the cellular segments was the HIV-nef
cryptic 5P splice sites 66 or 74 and the 3P splice acceptor sites
of cellular genes (Fig. 6B). Synthesis of these hybrid mRNAs
was con¢rmed by RT-PCR analysis utilizing CV1-B3/13
cDNA for the PCR reaction (Fig. 6A). In contrast, none of
the PCR products was obtained when cellular CV1-B3/13
Fig. 5. Northern blot analysis of CV1-B3/13 cells. The mRNA was
isolated from CV1-B3/13 (lane 1) and CV1-B3 cells (lane 2) and
subjected to Northern blot analysis. A: The nylon membrane was
hybridized with an HIV-Nef anti-sense DIG-labelled RNA probe
(DIG RNA labelling kit, Roche), exposure time was 10 min. Lane
C (control) contains the mRNA extracted from CV1-B3 cells 48 h
after transfection of the CMV-£ag-nef DNA. A*: The same blot as
shown in A but exposed for 15 h. B: The blot was stripped and re-
hybridized with the anti-sense KIAA1454 DIG-labelled RNA probe
(exposure time 3 h). C: The blot was again stripped and re-hybrid-
ized with the anti-sense PTPU DIG-labelled RNA probe (exposure
time 3 h). D: The same blot was stripped and re-hybridized with
a GAPDH anti-sense DIG-labelled RNA probe (exposure time
1 min).
Fig. 4. Western blot analysis. Anti-Nef immunoprecipitates from CV1-B3 cells (lane 1), CV1-B3/13 cells (lane 2) and CV1-768 cells (lane 3)
were subjected to Western blot analysis. A: The blot was incubated with Ab-2 anti-T-antigen, 10 min exposure time after chemiluminescence
detection. B: The blot was stripped and hybridized with £ag antibody; exposure time 30 min. The Nef/T hybrid protein, IgG and unspliced
Nef protein are indicated.
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DNA was used as a template for PCR ampli¢cation (Fig. 6A,
lane 3). We further mixed the HIV-nef cRNA with RNA
isolated from the CV1-B3 cells and performed RT-PCR anal-
ysis as described above. However, neither generation of the
HIV-nef/T-antigen nor of the HIV-nef/cellular hybrid RNA
molecules was demonstrable. Therefore, these results exclude
the possibility of heterologous trans-splicing being mimicked
by the jumping of reverse transcriptase from acceptor RNA
molecules to the 5P cryptic splice site of the HIV-nef donor
RNA during cDNA synthesis (data not shown).
In this investigation, we have only focused on the HIV-nef/
KIAA1454 and the HIV-NEF/PTPU trans-splice products.
Fig. 6. Characterization of trans-splicing products. A: Total RNA was extracted from CV1-B3 and CV1-B3/13 cells and converted into cDNA
utilizing the mdT primer for the ¢rst DNA strand synthesis. RT-PCR analysis of CV1-B3 cells (lane 1) and CV1-B3/13 cells (lane 2) was per-
formed utilizing di¡erent primer pairs, as indicated in each case. PCR analysis of genomic DNA from CV1-B3/13 cells (lane 3) was performed
in each case as a control. Products were separated on a 2.5% agarose gel and visualized by ethidium bromide staining. The size of the ampli¢ed
products is marked on the right. B: The table shows for each of the PCR products described above the 5P cryptic HIV-nef splice sites used in
the trans-splicing process, the accurate junction sequences of the two RNAs and the size of the expected hybrid proteins.
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The KIAA1454 cDNA was recently identi¢ed in human brain
cells [22], but the genomic sequence is still not known. This
cDNA encodes a 1117 amino acid protein of unknown func-
tion. The HIV-nef/KIAA1454 hybrid mRNA contains two
distinct segments. The junction between the two segments
(GAG/GAG) is the cryptic splice site 66 of the HIV-nef
RNA and the 3P splice site of the KIAA1454 RNA (codon
709) used by the cells for conventional cis-splicing to generate
the KIAA1454 mRNA. To verify whether the CV1-B3/13 cells
generate a shorter KIAA1454 mRNA isoform in a detectable
amount, the Northern blot (Fig. 5A) was stripped and re-hy-
bridized with a KIAA1454 anti-sense RNA probe. As shown
in Fig. 5B, lane 1, the CV1-B3/13 cells synthesize an addi-
tional KIAA1454 mRNA isoform which is also recognized
by the HIV-nef probe, but is not present in mRNA extracted
from the CV1-B3 cells (Fig. 5B, lane 2). The expected trans-
lation product of the HIV-nef/KIAA1454 mRNA is a hybrid
protein that contains the 66 amino acids of HIV-Nef in the
proximal part and the 408 amino acids of the KIAA1454
protein (amino acids 709^1117) in the distal part. To identify
the HIV-Nef/cellular hybrid proteins, CV1-B3/13 and CV1-B3
cell lysates were subjected to 2D electrophoresis. As shown in
Fig. 7A, multiple HIV-Nef protein isoforms were synthesized
in the CV1-B3/13 cells, but not in the CV1-B3 cells (Fig. 7B).
However, due to the lack of speci¢c antibodies, conclusive
identi¢cation of the hybrid proteins by gel electrophoresis
has not yet been possible.
The PTPU gene encodes a 1438 amino acid membrane-as-
sociated tyrosine phosphatase [23]. The expected HIV-nef/
PTPU hybrid protein contains 74 amino acids of HIV-Nef
and only 24 amino acids of the PTPU protein. This is due
to the fact that the 3P acceptor splice site used to generate
the hybrid mRNA molecule by heterologous trans-splicing is
not a conventional 3P splice site used for PTPU cis-splicing but
rather a cryptic 3P splice site. Moreover, this acceptor splice
site is not within the authentic reading frame of the PTPU
mRNA, and hence trans-splicing generates a new open read-
ing frame for only 24 amino acids (Fig. 8). Although only one
HIV-nef/PTPU trans-splice product could be identi¢ed by RT-
PCR, there are several PTPU mRNA isoforms detectable by
Northern blot analysis (Fig. 5C, lane 1) that are not synthe-
sized in CV1-B3 cells (Fig. 5C, lane 2). However, these iso-
forms were not further analyzed in this investigation.
To identify the HIV-Nef/PTPU hybrid protein, we gener-
ated the CMV-£ag-nef/PTPU DNA, which encodes the HIV-
Nef/PTPU hybrid protein, and transfected this DNA into CV1
cells. E⁄cient HIV-nef/PTPU mRNA synthesis was demon-
strable by RT-PCR and Northern blot analysis (data not
shown). However, the hybrid protein could not be detected
in transiently transfected cells or in cells of nef/PTPU positive
lines (CV1-nef/PTPU cells) neither by immuno£uorescence
staining, nor by Western blot analysis utilizing the anti-£ag
or the HIV-1 Nef BH10 antibody.
4. Discussion
In this investigation we obtained experimental evidence that
mammalian cells have the capability to generate viral/viral
and viral/cellular hybrid mRNA molecules by heterologous
trans-splicing. Formation of hybrid mRNA molecules was
observed between HIV-nef and SV40 T-antigen RNA and
between HIV-nef RNA and eight di¡erent cellular transcripts.
In each case, the 5P splice site was donated by the HIV-nef
RNA and the acceptor 3P splice site by the SV40 T-antigen or
by cellular transcripts (Fig. 6B).
So far the features of an RNA molecule that lead to trans-
splicing are not clear. We assume that RNA molecules that
contain cryptic splice sites, which cannot be used for cis-splic-
ing, are good candidates for heterologous trans-splicing.
Cryptic splice sites can be a genuine feature of a gene (e.g.
HIV-nef) or they can be generated and activated by point
mutation. In this regard it is noteworthy that splice site mu-
tations are frequently associated with human genetic diseases
[24,25]. One central question in heterologous trans-splicing is
Fig. 7. 2D immunoblot analysis. Protein extracts obtained from CV1-B3/13 cells (A) and CV1-B3 cells (B) were separated by 2D electrophoresis
and the blots were incubated with HIV-1 Nef BH10 antiserum. After incubation with the peroxidase-conjugated secondary antibody blots were
developed by enhanced chemiluminescence. The Nef-speci¢c proteins are indicated by arrows. Mr kDa, protein marker.
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how RNA molecules that are transcribed from di¡erent genes
¢nd each other. The current model proposes that the splice
sites form stable complexes with ribonucleoproteins and with
splice factors such as SR proteins [26,27] that mediate the
association of the two RNA molecules by protein^protein
interaction [8]. SR proteins have both exon-dependent and -
independent functions in pre-mRNA splicing [28]. These pro-
teins bind to purine-rich sequences called exon splicing en-
hancer (ESE), promoting both the assembly of the pre-spli-
ceosomal complex [27] and the subsequent splicing steps [29].
Experiments carried out with nuclear cell extracts have shown
that ESE sequences are necessary for in vitro trans-splicing
[30,31]. The importance of these purine-rich sequences for
trans-splicing in vivo was further con¢rmed by analyzing car-
nitine octanoyltransferase (COT) mRNA processing in Cos7
monkey cells. In contrast to the rat COT gene, the second
exon of the monkey COT gene lacks an ESE and the cells
do not perform homologous COT trans-splicing. However,
following intranuclear microinjection of rat COT pre-
mRNA, monkey cells performed e⁄cient homologous rat
COT trans-splicing (C.C. and A.G., personal observation).
Furthermore, Cos7 cells were able to generate rat COT/T-
antigen hybrid mRNA molecules by heterologous trans-splic-
ing after pre-mRNAs injection [32]. In this regard, it is of
interest that ESE-like sequences have been found in the vicin-
ity of the 3P splice site in all acceptor RNA molecules de-
scribed in the present investigation (e.g. SV40 T-antigen;
Fig. 1B).
Moreover, direct RNA^RNA association via complementa-
ry sequences may additionally facilitate heterologous trans-
splice e⁄ciency as it was shown for ribozyme trans-splicing
[33,34] and for homologous SV40 T-antigen trans-splicing [8].
From the nucleotide sequence, it can be deduced that stabili-
zation of the trans-splicing pre-spliceosome complex might be
a result of direct molecular interactions by base pairing be-
tween HIV-nef and SV40 T-antigen RNAs. Since the genomic
sequences of PTPU and KIAA1454 genes are still unknown, it
is uncertain whether base pairing between the HIV-nef RNA
and these cellular transcripts could occur.
We further hypothesize that factors not constitutively ex-
pressed are also involved in homologous and heterologous
trans-splicing. This assumption is based on the observation
that the e⁄ciency of these mRNA processing events increased
in cells of di¡erent independent lines from low to high passage
without a detectable DNA rearrangement. In the case of ho-
mologous SV40 T-antigen mRNA trans-splicing (T1-mRNA),
we observed that the e⁄ciency of T1-mRNA synthesis was
extremely low between cell passages 10 and 20, but the T1-
mRNA and T1-antigen became dominant at higher passages
(in preparation for publication). An increase in the heterolo-
gous HIV-nef trans-splicing e⁄ciency (e.g. HIV-nef/T-antigen,
HIV-nef/PTPU) from approximately 0.1 to 10%, relative to the
total amount of HIV-nef transcript, was also observed with
continuous culture of the CV1-B3/13 cells (data not shown).
Although it is now clear that mammalian cells have the
capability to generate hybrid protein molecules via trans-splic-
ing, we can only speculate about the biological signi¢cance of
these proteins. Synthesis of hybrid proteins may have di¡erent
  
 
 
Fig. 8. Heterologous trans-splicing nef/PTPU model. A: Schematic view of the HIV-nef gene (amino acids 1^206) and partial view of the gene
PTPU (amino acids 1^1650). The position and the sequence of the 5Pcry nef splice site (74) and of the 3Pcry PTPU splice site (677) are indicated.
B: Schematic view of the nef/PTPU hybrid mRNA. The proximal segment is the HIV-nef sequence (amino acids 1^74) and the distal segment
the PTPU sequence (amino acids 677*^701*). C: Schematic view of the predicted Nef/PTPU hybrid protein (amino acids 1^98).
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e¡ects. Among others, hybrid molecules may have new func-
tions distinct from those of the proteins encoded in donor and
acceptor RNAs. The emergence of new functions as well as a
change in the subcellular localization can be expected through
the formation of hybrid proteins such as HIV-Nef/KIAA1454
or HIV-Nef/T-antigen, where trans-splicing maintains the au-
thentic reading frame of both the donor and the acceptor
RNAs. On the other hand, trans-splicing could lead to a re-
duction in the number of both, authentic HIV-Nef and cellu-
lar proteins, considering that a signi¢cant portion of the HIV-
nef transcript is engaged in heterologous trans-splicing in
CV1-B3/13 cells. Through the change in the reading frame
of the PTPU acceptor RNA segment by heterologous trans-
splicing, the resulting hybrid protein lacks all the functional
domains of the PTPU. However, generation of a similar HIV-
Nef/PTPU hybrid molecule cannot be expected in human cells
since the human PTPU gene does not contain the cryptic
3P splice site present in the monkey gene. Consequently, tran-
siently transfected Jurkat cells failed to generate the HIV-nef/
PTPU hybrid mRNA, but they do have the capability to gen-
erate hybrid molecules such as HIV-nef/T-antigen mRNA and
protein molecules via heterologous trans-splicing (data not
shown). This implies that cells of HIV-infected patients may
also synthesize viral/viral and viral/cellular hybrid mRNA and
protein molecules by heterologous trans-splicing. However,
the possible signi¢cance of this mRNA processing mechanism
for the viral life cycle and for the HIV-induced pathology
remains speculative.
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